EGFR and neoplasm: Overexpression of Claudin18.2 may activate related signaling pathways, like SPAK-p38 MAPK signaling pathway, epidermal growth factor receptor (EGFR)/extracellular signal-regulated kinase (ERK) signaling et al., which leads to tumor cell proliferation (20–22).